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KEY MESSAGE 
This is the first study to indicate herd protection from infant PCV13 on adult non-bacteraemic 
pneumococcal pneumonia 
ABSTRACT 
Infant 13-valent pneumococcal conjugate vaccination (PCV13) was introduced to the UK in 2010. Its 
impact on serotypes implicated in adult non-bacteraemic pneumococcal pneumonia is not known. 
 
Beginning in 2008, a five-year prospective cohort study of adults admitted to hospital with community-
acquired pneumonia (CAP) was conducted. Pneumococcal serotype was established using a validated 
multiplex immunoassay (Bio-Plex). 
 
The overall incidence for hospitalised CAP and pneumococcal CAP was 79.9 (95%CI76.6-83.3) and 
23.4 (95%CI21.6-25.3) per 100,000 population respectively. A decline in CAP (incidence rate ratio (IRR) 
per year 0.96, 95%CI0.94-0.99; p=0.016) and pneumococcal CAP (IRR per year 0.84, 95%CI0.80-0.89; 
p<0.001) was observed over the five-year period of the study. Between the pre- and post PCV13 periods 
of the study, the incidence of CAP due to serotypes included in the 7-valent pneumococcal conjugate 
vaccine declined by 88% (IRR 0.12, 95%CI0.08-0.20,p<0.001), and CAP due to the additional 6 
serotypes in PCV13 declined by 30% (IRR 0.70, 95%CI0.51-0.96,p=0.024).  
 
Incidence of adult pneumococcal pneumonia declined over the last five years, with serotypes included 
in PCV13 declining post-PCV13 introduction, indicating early herd protection effects from PCV13 infant 
vaccination on adult non-bacteraemic disease. These effects may accrue over the coming years with 
implications for national pneumococcal vaccination policies in adults. 
INTRODUCTION 
Community-acquired pneumonia (CAP) is the leading cause of sepsis presenting to hospitals, and in 
the UK, results in over 100,000 admissions per year.1 ,2 The associated mortality is 14-25%, with older 
age groups particularly at risk.2 ,3 Streptococcus pneumonia is the pathogen implicated in 37-48% of 
CAP.3 ,4 A seven-valent pneumococcal conjugate vaccine (PCV7) was introduced into the infant 
immunisation programme in the UK in September 2006, followed by a 13-valent vaccine (PCV13) in 
April 2010. For adults in the UK, only the 23-valent pneumococcal polysaccharide vaccine (PPV23) has 
been recommended for routine immunisation, except in severely immunocompromised adults where 
the recommendation is for a single dose of PCV13 followed by PPV235 
Following the introduction of PCVs, a reduction in invasive pneumococcal disease (IPD) and IPD due 
to vaccine-type serotypes has been reported among children in several countries including the UK, with 
varying degrees of serotype replacement with non-vaccine-type serotypes.6 ,7 Reductions in the 
incidence of PCV7-type IPD were also seen in the unvaccinated adult population due to herd protection 
effects. However, invasive pneumococcal disease accounts for only 7-14% of pneumococcal CAP in 
adults presenting to hospitals.8 ,9 Changes in pneumococcal serotype distribution implicated in adult 
non-bacteraemic pneumococcal disease as a consequence of the introduction of PCV13 have not been 
reported to date.  
A key economic evaluation from 2012 on the cost effectiveness of vaccinating at risk groups aged ≥2 
years with PCV13, reported that the 2 most influential variables on outcome were the assumed herd 
protection effects of infant pneumococcal vaccination and the direct vaccine effectiveness against non-
bacteraemic pneumococcal disease.10 This study addresses the first of these factors. 
We report the changes in pneumococcal serotypes in the years prior to and following PCV13 
introduction in the UK from a five-year prospective cohort study of adults hospitalised with 
predominantly non-bacteraemic CAP.  
METHOD 
Beginning in September 2008, a prospective cohort study of adults with CAP admitted to two large 
teaching hospitals in Nottingham, UK was conducted over five years. Adults (≥16 years) with symptoms 
suggestive of lower respiratory tract infection (at least one of breathlessness, cough, sputum or fever), 
with new infiltrates on chest radiography consistent with pneumonia, and treated by the admitting clinical 
team for CAP, were included in this study. Exclusion criteria were post obstruction pneumonia due to 
lung cancer, active tuberculosis, discharge from hospital within the preceding ten days, and adults with 
aspiration pneumonia. Study investigators attended acute admission units, hospital wards and critical 
care units on a daily basis to identify adults with CAP.  Following informed consent, a standardised 
proforma was used to collect information regarding patient demographics, clinical information, 
microbiological investigations, radiological findings and outcome measures. If an adult was unable 
consent to the study due to acute confusion or cognitive impairment, informed assent was obtained 
from a relative. All adults were managed at the discretion of the admitting clinical team. Ethics approval 
was granted by the Nottingham Regional Ethics Committee. 
Urine samples were collected from participants following admission and sent to the Nottingham 
University Hospitals’ Department of Clinical Microbiology, a regional Public Health England (PHE) 
laboratory. Samples were tested using the BinaxNOW® (Alere) immunochromatographic test kit 
according to manufacturer’s instructions and then placed in frozen storage. The sensitivity and 
specificity of the BinaxNOW® test in a recent meta-analysis was 74% and 97%, respectively.11  Samples 
were subsequently transported in batches to the Respiratory and Vaccine Preventable Bacteria 
Reference Unit (RVPBRU) at PHE Colindale, London. Pneumococcal serotyping was carried out using 
a validated multiplex immunoassay (Bio-Plex; Bio-Rad) capable of detecting 14 pneumococcal 
serotypes/serogroups (1, 3, 4, 5, 6A/C, 6B, 7F/A, 8, 9V, 14, 18, 19A, 19F and 23F) with a sensitivity 
and specificity of 79% and 99% respectively.12 The Bio-Plex assay does not differentiate between 
serotypes 6A versus 6C, 7F versus 7A, and the individual serotypes within serogroup 18 (18F, 18A, 
18B and 18C) In bacteraemic adults, serotype was also determined using slide agglutination using the 
full set of serotyping latex and factor serum available from Statens Serum Institut Copenhagen. This 
method is capable of determining all serotypes of pneumococci except the newly described serotype 
11E. All included adults (n=2,229) had BinaxNOW® and Bio-Plex testing performed, and 2,106 (94.5%) 
had blood cultures performed. Adults with a positive BinaxNOW® test, Bio-Plex test or blood culture for 
Streptococcus pneumoniae were deemed to have pneumococcal CAP. Respiratory samples were not 
used for the diagnosis of pneumococcal disease or determination of pneumococcal serotype in this 
study, due to the poor sensitivity and specificity reported in previous studies.13 ,14  
Pneumococcal serotypes were categorised as follows: 4, 6B, 9V, 14, 18C, 19F and 23F  as ‘PCV7 
serotypes’; 1, 3, 5, 6A/C, 7F/A and 19F as ‘additional PCV13 serotypes’, and the remaining detected 
serotypes (serotype 8 from Bio-Plex  and serotypes obtained from bacteraemic adults that are not 
amongst the detectable Bio-Plex serotypes) as ‘other serotypes’. Individuals with CAP who were 
BinaxNOW® positive, but were Bio-Plex negative and blood culture negative for Streptococcus 
pneumoniae were deemed to have ‘untyped’ pneumococcal CAP.  
Annual incidence rates were derived using data from the Office of National Statistics (ONS) for the 
Greater Nottingham area, which also provided local population data stratified according to age groups 
(16-24, 25-44, 45-64, 65-74, 75-84 and 85+ years).15  In the first analysis, trends in the overall incidence 
of CAP, pneumococcal CAP and serotype categories over the study period were examined (September 
2008-August 2013). For the  second analysis comparing periods before and after PCV13 introduction,  
incidence rates in the first year of the study (September 2008-August 2009) were compared with the  
overall incidence rate for years three to five  combined (September 2010-August 2013). As PCV13 was 
introduced in April 2010 in the UK, the second year of the study (September 2009-August 2010) was 
considered to be the ‘transitional period’ for the change from PCV7 to PCV13.  
Statistical analyses were performed in STATA (V.12, StataCorp, College Station, Texas). Poisson 
regression models were used to assess year to year variation in incidence, for linear trend analysis, 
and comparison of incidence between pre- and post-PCV13 periods, together with 95% confidence 
intervals (CIs).   
 
RESULTS 
Of 2,702 eligible adults identified over the five-year period, 2,321 consented to the study.  Of these, 16 
were excluded due to an alternative final diagnosis and 76 were excluded as they were unable to 
provide a urine sample, leaving 2,229 in the cohort for analyses. The median age of the cohort was 
71.0 years (inter-quartile range(IQR) 55.1-80.5) and 992(44.5%) were female (table 1). Pneumonia 
severity was low, moderate and high in 1,042(46.8%), 673(30.2%) and 514(23.1%) adults, respectively; 
267(12.0%) adults were admitted to a critical care unit and 30-day mortality was 8.2%(n=183). Disease 
severity according to study year is shown in supplementary table 1. The percentages of children that 
had received two doses of PCV by their first birthday in the Nottingham City Primary Care Trust area 
were 92.1%, 94.2%, 95.0%, 95.8%, 95.5% and 96.2% for the years 2008, 2009, 2010, 2011, 2012 and 
2013, respectively.16 The vaccine uptake rates of the 23-valent pneumococcal polysaccharide vaccine 
(PPV23) in adults aged ≥65 years in the UK were 69.0%, 68.2%, 70.5%, 68.3% and 69.1% for the years 
2008-09, 2009-10, 2010-11, 2011-12 and 2012-13, respectively.16 
Pneumococcal aetiology was identified in 653(29.3%) adults (table 1). Of these, 407(62.3%), 
411(62.9%) and 87(13.3%) had a positive BinaxNOW® test, Bio-Plex assay and blood culture result 
respectively (supplementary figure 1). A serotype or serogroup was determined in 444 of 653(68.0%) 
adults with pneumococcal aetiology; 8 had two serotypes/serogroups identified simultaneously 
(15A+18(n=1), 1+22F(n=1), 4+1(n=2), 4+8(n=3) and 6B+9V(n=1)) and were excluded from the 
analyses specific to serotype trends. Of 1368 adults aged ≥ 65 years of age, 753(55.0%) had received 
pneumococcal polysaccharide vaccination (PPV23); 213(55.6%) of 383 adults aged ≥ 65 years with 
pneumococcal pneumonia had received PPV23 vaccination.  
Trends in hospitalised CAP and pneumococcal pneumonia 
The overall incidence of CAP for the duration of the study was 79.9(95%CI 76.6-83.3) per 100,000 
population (table 2). A decline in CAP incidence was observed over the five years (incidence rate ratio 
(IRR) per year 0.96, 95%CI 0.94-0.99; p=0.016)(table 3). The largest absolute and relative reduction in 
CAP incidence was seen in adults ≥85 years (rate difference between 2008-09 and 2012-13, 625.0 
cases per 100,000 population; relative reduction 59.4%). Incidence rates for CAP increased with older 
age groups across all years (IRR per increasing age group 2.25, 95%CI 2.19-2.32; p<0.001). 
The overall incidence for pneumococcal CAP was 23.4(95%CI 21.6-25.3) per 100,000 population over 
the five-year period. A decline in pneumococcal CAP incidence rate was observed over the five years 
(IRR per year 0.84, 95%CI 0.80-0.89; p<0.001), with the largest absolute and relative reduction seen 
in the oldest age group (rate difference between 2008-09 and 2012-13, 250 cases per 100,000 
population, relative reduction 60.0%) (tables 2 and 3, and supplementary figure 2). Older age groups 
consistently had higher incidence rates of pneumococcal CAP throughout the five years (IRR per 
increasing age group 2.17, 95%CI 2.05-2.29; p<0.001).  
 
Trends in pneumococcal serotypes 
Of 436 adults with a single pneumococcal serotype identified, 94 (21.6%), 247 (56.7%) and 95 (21.8%) 
had CAP due to PCV7, additional PCV13, and ‘other’ serotypes respectively. The overall incidence 
rates of CAP due to PCV7 serotypes, additional PCV13 serotypes, and other serotypes were 3.4(95%CI 
2.7-4.1), 8.9(95%CI 7.8-10.0) and 3.4(95%CI 2.8-4.2) per 100,000 population, respectively. The 
incidence of CAP due to PCV7 serotypes was highest in 2008-09 (11.1(95%CI 8.5-14.2) cases per 
100,000 population), after which rates declined to 1.6 (95%CI 0.7-3.1) cases per 100,000 population in 
2009-10, and remained low throughout the remainder of the study (table 2 and figure 1). The five-year 
linear trend in CAP incidence due to PCV7 serotypes showed a marked decline (IRR per year 0.52, 
95%CI 0.43-0.62, p <0.001)(table 3). The predominant PCV7 serotypes identified were serotypes 4 and 
14, accounting for 70.2% of all PCV7 serotypes (figure 2). Reductions in CAP due to serotypes 4 and 
14 were observed over the five-year period (IRR per year 0.41(95%CI 0.24-0.69) and 0.28(95%CI 0.19-
0.41) for serotypes 4 and 14, respectively). The remaining PCV7 serotypes (6B, 9V, 18C, 19F and 23F) 
were much less commonly implicated (<10 cases each over the study period). 
Pneumonia due to additional PCV13 serotypes peaked during 2009-10 (11.5(95%CI 8.8-14.6) cases 
per 100,000 population), but gradually declined over the subsequent three years (8.1(95%CI 5.9-10.8), 
7.9(95%CI 5.7-10.6) and 6.3(95%CI 4.4-8.7) cases per 100,000 population for years 2010-11, 2011-12 
and 2012-13, respectively)(table 2 and figure 2). The CAP incidence rate due to additional PCV13 
serotypes declined between years one and five (IRR per year 0.87, 95%CI 0.80-0.95, p=0.002) (table 
3). CAP due to serotypes 3 and 5 peaked during 2009-10, and declined thereafter (figure 2). Five-year 
linear trends showed a decline in CAP due to serotypes 1, 3 and 5 (IRR per year 0.68,95%CI 0.56-0.82, 
p<0.001; 0.58,95%CI 0.42-0.82, p=0.002; and 0.60, 95%CI 0.43-0.84, p=0.003 for serotypes 1, 3 and 
5, respectively). However, CAP due to serotype 7F/A increased over the five years (IRR per year 1.37, 
95%CI 1.15-1.63, p=0.001), reaching a peak in 2012-13 with an incidence of 4.5 (95%CI 2.9-6.6) cases 
per 100,000 population. The ‘other’ serotypes implicated in adults admitted with CAP by study year are 
shown in supplementary table 2. 
 
Comparison between pre- and post-PCV13 vaccination periods 
The incidence rates for CAP and pneumococcal CAP in the post-PCV13 period were lower in 
comparison to the pre-PCV13 period (IRR 0.85(95%CI 0.76-0.94) and 0.52(95%CI 0.44-0.62) for CAP 
and pneumococcal CAP, respectively) (table 4). Between the two periods, CAP due to PCV7 serotypes 
and additional PCV13 serotypes also declined, although the magnitude of reduction was greater for 
PCV7-serotype CAP (88% reduction in CAP due to PCV7 serotypes versus 30% reduction in CAP 




To our knowledge, this is the first study to investigate the impact of PCV13 on pneumococcal serotypes 
implicated in a predominantly non-bacteraemic cohort of adult pneumococcal CAP. The key findings 
were that: 1) the incidence of hospitalised pneumococcal pneumonia has been declining over the last 
5 years, including the years following PCV13 introduction; 2) the incidence of CAP due to additional 
PCV13 serotypes declined by 30% in the 2 years following PCV13 introduction compared to  pre-PCV13 
and 3) ongoing declines in PCV7-related disease were evident 3 to 4 years after PCV7 introduction; the 
incidence of CAP due to PCV7 serotypes declined by 48% over the course of the study.   
Although studies have previously reported a decline in the incidence of IPD in adults following PCV 
introduction to infant immunisation schedules, 6 ,7 few have investigated its impact on the incidence of 
CAP and non-bacteraemic pneumococcal CAP. Analyses from hospital coding databases in the USA 
have reported a decline in  rates of  CAP and non-bacteraemic CAP following infant PCV7 and PCV13 
introduction.17,18 A study from the UK of community diagnoses of CAP in children and adolescents (0-
18 years)  found a 35% decline in pneumonia consultations following PCV7 introduction between 2006-
09.19 However, the accuracy of pneumonia diagnoses in coding databases is not verified.  
This study observed a 4% and 16% decline in CAP and pneumococcal CAP incidence rates per year, 
respectively. Contemporary national IPD surveillance data from the UK report a 22% decline in IPD 
rates between 2008-10 and 2012-13, amongst all age groups.20 A high incidence rate for CAP was 
observed during 2011-12 despite a continued decline in pneumococcal CAP in this study. No significant 
differences in the number of other causative pathogens for CAP were seen during this period in 
comparison to other years and these numbers remained relatively stable over the five years 
(supplementary table 3); however, testing for pathogens other than S. pneumoniae was at the discretion 
of attending clinical teams and routine testing for atypical pathogens was not conducted. National 
surveillance data from PHE revealed a high number of cases of Mycoplasma pneumoniae in 2011-12, 
with similar numbers to 2006 and the highest since 2003 in the UK; hence 2011 – 12 coincided with a 
‘Mycoplasma year’ which is recognised to peak every 4 – 7 years. 21 ,22   National virological surveillance 
reported relatively lower influenza rates in 2011-12 in comparison to previous years.23 Influenza 
vaccination uptake amongst adults ≥65 years (74.1%, 72.4%, 72.8%, 74.0% and 73.4% for the years 
2008-09, 2009-10, 2010-11, 2011-12 and 2012-13, respectively) and ‘at risk’ individuals aged 6 months 
to <65 years (47.1%, 51.6%, 50.4%, 51.6% and 51.3% for the years 2008-09, 2009-10, 2010-11, 2011-
12 and 2012-13, respectively) remained relatively stable in the UK over the five years of the study.16  
 
In our study, the largest annual reduction in CAP incidence was in adults aged ≥85 years. Database 
analyses from the USA reported the largest decline in CAP hospitalisations in adults ≥85 years,17 with 
similar findings in IPD cohorts elsewhere;7 although both these studies compared periods before and 
after PCV7 introduction. Adults at the extremes of age are likely to have the greatest potential for 
disease reduction from PCVs as rates of disease were highest in these adults prior to PCV introduction. 
Contemporary national IPD data from the UK  showed the largest absolute reduction in IPD rates among 
adults aged ≥65 years,  although this decline was attenuated due to a concurrent increase in non-
PCV13 serotypes.20  The incidence of CAP remains strongly age dependent,24 and the impact of a 
continually ageing population on CAP incidence in the future requires close observation.25  
Additional PCV13 serotypes accounted for 57% of all serotyped pneumococcal CAP during the study, 
with the bulk of disease due to serotypes 1, 7F/A and 19A. The incidence of CAP due to additional 
PCV13 serotypes was highest during the winter months of 2009-10, prior to PCV13 introduction in April 
2010. Exclusion of this ‘transitional year (2009-10)’ from the analyses comparing pre and post-PCV13 
periods is likely to have led to a conservative estimate of the reduction in incidence rates for CAP due 
to additional PCV13 serotypes.  
The incidence of CAP due to PCV7 serotypes declined most markedly between years 1 and 2 of this 
study, corresponding to the third year post-PCV7 introduction, and remained low thereafter. A 
statistically non-significant increase in the incidence of CAP due to serotypes 6B and 19F was observed 
in the final year of the study, although serotype numbers were small, and therefore these specific trends 
should be interpreted with caution. National IPD surveillance data from the UK found that the majority 
of vaccine failures among the PCV7 serotypes were due to serotypes 6B and 19F in the post PCV7 
period.20 Vaccine failures related to serotype 19F may be due to resistance to complement deposition 
and lower sensitivity to opsonophagocytic killing.26 Inability to effectively clear nasopharyngeal carriage 
of serotype 19F in children may translate into a lack of ‘herd protection’ against serotype 19F amongst 
adults.  
Data from IPD cohorts in the UK and the USA in the years following PCV7 introduction reported 
serotypes 1, 7F and 19A as significant replacement serotypes.6 ,7 Although the incidence of CAP due 
to serotypes 1, 3 and 5 declined during the study, CAP due to serotype 7F/A increased. This finding 
was in contrast to adult IPD data from the UK and paediatric IPD data from France during the post-
PCV13 period.20 ,27 Although the Bio-Plex assay used in this study was unable to differentiate between 
serotypes 7F and 7A, it is likely that the majority of implicated serotypes were 7F, as previous studies 
of both IPD and non-invasive pneumococcal disease have shown that serotype 7A is rarely implicated,6 
,7 ,28 Differences in serotypes implicated in contemporary cohorts of IPD and non-bacteraemic 
pneumococcal disease have been demonstrated previously.29 Further, unvaccinated adults are likely 
to have a residual burden of pneumococcal disease due to serotypes included in PCVs, and herd 
protection effects are likely to manifest slower, in comparison to the vaccinated paediatric population.6 
,7   
 
Strengths and weaknesses 
A major strength of this large prospective cohort study is robust case ascertainment of radiologically 
confirmed CAP drawn from a relative stable population over a five-year period. The two teaching 
hospitals in this study together serve the catchment area of Greater Nottingham comprising 557,800 
adults.15 Comprehensive in-patient services have been provided for this population by the same two 
hospitals for more than two decades. Relative to other regions of the UK, Nottinghamshire ranks as 
‘average’ with regard to indices of health, socioeconomic deprivation and ethnic diversity.30 ,31The base 
population is therefore a representative reflection of the UK.   
The main limitation in our study is that reliable inferences cannot be drawn regarding trends in CAP 
rates due serotypes not included in PCV13. Around 25-38% of the pneumococcal cohort was ‘untyped’ 
over the five-year period of the study (supplementary table 4); this mainly represents the proportion of 
cases that were BinaxNOW® positive but Bio-Plex negative. Although the incidence rates of ‘untyped’ 
pneumococcal CAP remained relatively stable over the study period (5.7-8.7 per 100,000 adults), 
national IPD data demonstrate a 22% and 31% increase in non-PCV13 serotypes in adults aged 45-64 
and ≥65, respectively, between 2008-10 and 2012-13 (unpublished data from PHE). Extrapolating the 
proportion of non-PCV13 serotypes in bacteraemic adults (28.7%) to the ‘untyped’ pneumococcal 
cohort in this study, showed a relatively stable number of adults with non-PCV13 serotypes over the 
five years (supplementary table 5). 
The incidence of CAP in this study was lower in comparison to a previous study in the UK based on 
hospital coding data from the pre-PCV era.2  This difference is partly explained by inaccuracies in the 
coding of CAP within the UK HES database; various studies indicate that in about 50% of coded 
pneumonias, there is no evidence of pneumonia on the chest radiograph.32 ,33 Some of the difference 
may also be due to a true reduction in the overall incidence of CAP in recent years compared to the 
pre-PCV period. 17 ,34 
The severity of CAP in hospitalised adults remained stable during the five-year period of our study, 
reflecting a consistent threshold for hospital admission for pneumonia, in line with national guidelines 
over this period. As this study did not encompass patients treated for pneumonia in the community, it is 
theoretically possible that the incidence of overall pneumonia (community and hospital treated) has 
remained stable over the study period, but that the overall severity of pneumonia has reduced with a 
resultant decrease in the rate of hospitalisations. Further community based studies are needed to 
explore this potential. 
The combined sensitivity of the BinaxNOW®  (74%) and Bio-Plex tests (79%) utilised in this study is 
considerably higher than conventional cultural techniques, especially following the administration of 
antibiotics. 11 ,12 ,14 Nevertheless, a proportion of pneumococcal disease may have been missed  leading 
to an underestimate of the true incidence of disease.  This is unlikely to affect the analysis of trends in 
incidence rates of pneumonia due to PCV serotypes. The specificity of the BinaxNOW® test and Bio-
Plex assay is ≥97%.11 ,12  
 
In conclusion, in a population with high infant PCV coverage, incidence rates of adult pneumococcal 
pneumonia have declined over the last 5 years. The introduction of PCV13 infant vaccination was 
followed by reductions in CAP due to PCV13 serotypes indicating early herd protection effects on adult 
bacteraemic and non-bacteraemic disease which may continue to accrue, as observed following PCV7 
introduction.  These data have implications for pneumococcal vaccination policies in adults as the 
residual burden of PCV13 serotype disease in adults following implementation of childhood 
immunisation may be too low for an adult programme to be cost-effective.  
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  CAP cohort (n=2229) Pneumococcal cohort (n=653) 
Demographics    
Age (years)* 71.0 (55.1-80.5) 69.2 (50.2-79.8) 
Male 1237 (55.5) 326 (49.9) 
Nursing home residence 93 (4.2) 30 (4.6) 
WHO performance status ≥2 346 (15.5) 57 (16.0) 
     
Co-morbid illness    
Charlson Comorbidity Index* 4.0 (3.0-6.0) 4.0 (2.0-6.0) 
Malignancy 170 (7.6) 40 (6.1) 
Liver disease 22 (1.0) 10 (1.5) 
Congestive cardiac failure 144 (6.5) 36 (5.5) 
Ischaemic heart disease 396 (17.8) 112 (17.2) 
Chronic kidney disease 155 (7.0) 48 (7.4) 
Asthma 265 (11.9) 85 (13.0) 
COPD 475 (21.3) 117 (17.9) 
Diabetes 307 (13.8) 84 (12.9) 
Stroke 201 (9.0) 68 (10.4) 
Dementia 47 (2.1) 21 (3.2) 
HIV 11 (0.5) 4 (0.6) 
     
Disease severity    
CURB65 0-1 1042 (46.8) 272 (41.7) 
CURB65 2 673 (30.2) 199 (30.5) 
CURB65 3-5 514 (23.1) 182 (27.9) 
     
Outcomes    
ICU admission 267 (12.0) 95 (14.5) 
30-d IP mortality 183 (8.2) 41 (6.3) 
CAP, community-acquired pneumonia; WHO, World Health Organization; COPD, chronic obstructive pulmonary disease, HIV, Human Immunodeficiency Virus, 
ICU, intensive care unit, IP, in-patient, CURB65 confusion, urea>7 mmol/l, respiratory rate >30 breaths per minute, systolic blood pressure <90 mmHg or 
diastolic blood pressure ≤60 mmHg, age ≥65 years 
All values given as n(%) unless stated otherwise  
* Median (IQR) 
 





Year 1 (2008-09) Year 2 (2009-10) Year 3 (2010-11) Year 4 (2011-12) Year 5 (2012-13) 
n 
Incidence per 100,000 
(95% CI) n 
Incidence per 100,000 
(95% CI) n 
Incidence per 100,000 
(95%CI) n 
Incidence per 100,000 
(95% CI) n 
Incidence per 100,000 
(95%CI) 
CAP 506 90.7 (83.0-99.0) 439 78.7 (71.5-86.4) 359 64.4 (57.9-71.4) 560 100.4 (92.3-109.1) 365 65.4 (58.9-72.5) 
16-24  16 14.0 (8.0-22.7) 6 5.3 (1.9-11.4) 11 9.6 (4.8-17.2) 23 20.1 (12.8-30.2) 15 13.1 (7.4-21.6) 
25-44 50 27.9 (20.7-36.7) 60 33.4 (25.5-43.0) 51 28.4 (21.2-37.4) 61 34.0 (26.0-43.7) 49 27.3 (20.2-36.1) 
45-64 97 59.7 (48.4-72.8) 91 56.0 (45.1-68.7) 82 50.4 (40.1-62.6) 131 80.6 (67.4-95.6) 95 58.4 (47.3-71.4) 
65-74 113 201.4 (166.0-242.2) 89 158.7 (127.4-195.2) 77 137.2 (108.3-171.6) 107 190.7 (156.3-230.5) 77 137.2 (108.3-171.6) 
75-84 129 360.3 (300.8-428.1) 111 310.1 (255.1-373.4) 91 254.2 (204.7-312.1) 148 413.4 (349.5-485.6) 88 245.8 (197.2-302.8) 
85+ 101 1052.1 (856.9-1278.4) 82 854.2 (679.3-1060.2) 47 489.6 (359.7-651.0) 90 937.5 (753.9-1152.3) 41 427.1 (306.5-579.4) 
Pneumococcal 
CAP 
               
196 35.1 (30.4-40.4) 150 26.9 (22.8-31.6) 100 17.9 (14.6-21.8) 92 16.5 (13.3-20.2) 115 20.6 (17.0-24.8) 
16-24  6 5.2 (1.9-11.4) 4 3.5 (1.0-9.0) 3 2.6 (0.5-7.7) 3 2.6 (0.5-7.7) 6 5.2 (1.9-11.4) 
25-44 22 12.3 (7.7-18.6) 26 14.5 (9.5-21.2) 22 12.3 (7.7-18.6) 10 5.6 (2.7-10.2) 19 10.6 (6.4-16.5) 
45-64 40 24.6 (17.6-33.5) 31 19.1 (13.0-27.1) 24 14.8 (9.5-22.0) 20 12.3 (7.5-19.0) 26 16.0 (10.4-23.4) 
65-74 39 69.5 (49.4-95.0) 28 49.9 (33.2-72.1) 22 39.2 (24.6-59.4) 20 35.6 (21.8-55.1) 23 41.0 (26.0-61.5) 
75-84 49 136.9 (101.3-181.0) 34 95.0 (65.8-132.7) 18 50.3 (29.8-79.5) 24 67.0 (43.0-99.8) 25 69.8 (45.2-103.1) 
85+ 40 416.7 (297.7-567.4) 27 281.2 (185.3-409.2) 11 114.6 (57.2-205.0) 15 156.2 (87.4-257.7) 16 166.7 (95.3-270.7) 
PCV7 CAP 
               
62 11.1 (8.5-14.2) 9 1.6 (0.7-3.1) 8 1.4 (0.6-2.8) 2 0.4 (0.0-1.3) 13 2.3 (1.2-4.0) 
16-24  0 0 1 0.9 (0.0-4.9) 0 0 0 0 0 0 
25-44 4 2.2 (0.6-5.7) 0 0 1 0.6 (0.0-3.1) 0 0 3 1.7 (0.3-4.9) 
45-64 12 7.4 (3.8-12.9) 3 1.8 (0.4-5.4) 2 1.2 (0.0-4.4) 1 0.6 (0.0-3.4) 1 0.6 (0.0-3.4) 
65-74 15 26.7 (15.0-44.1) 1 1.8 (0.0-9.9) 3 5.3 (1.1-15.6) 1 1.8 (0.0-9.9) 4 7.1 (1.9-18.3) 
75-84 14 39.1 (21.4-65.6) 1 2.8 (0.1-15.6) 1 2.8 (0.1-15.6) 0 0 2 5.6 (0.7-20.2) 
85+ 17 177.1 (103.2-283.5) 3 31.2 (6.4-91.3) 1 10.4 (0.3-58.0) 0 0 3 31.2 (6.4-91.3) 
Additional 
PCV13 CAP 
               
59 10.6 (8.0-13.6) 64 11.5 (8.8-14.6) 45 8.1 (5.9-10.8) 44 7.9 (5.7-10.6) 35 6.3 (4.4-8.7) 
16-24  1 0.9 (0.0-4.9) 1 8.7 (4.2-16.1) 2 1.7 (0.2-6.3) 3 2.6 (0.5-7.7) 3 2.6 (0.5-7.7) 
25-44 9 5.0 (2.3-9.5) 15 8.4 (4.7-13.8) 13 7.2 (3.9-12.4) 4 2.2 (0.6-5.7) 6 3.3 (1.2-7.3) 
45-64 10 6.2 (3.0-11.3) 16 9.8 (5.6-16.0) 11 6.7 (3.4-12.1) 12 7.4 (3.8-12.9) 9 5.5 (2.5-10.5) 
65-74 13 23.2 (12.3-39.6) 11 19.6 (9.8-35.1) 10 17.8 (8.6-32.8) 13 23.2 (12.3-39.6) 7 12.5 (5.0-25.7) 
75-84 16 44.7 (25.6-72.6) 11 30.7 (15.3-55.0) 4 11.2 (3.0-28.6) 7 19.6 (7.9-40.3) 8 22.3 (9.6-44.0) 
85+ 10 104.2 (50.0-191.6) 10 104.2 (50.0-191.6) 5 52.1 (16.9-121.6) 5 52.1 (16.9-121.6) 2 20.8 (2.5-75.3) 
Other CAP 
               
24 4.3 (2.8-6.4) 23 4.1 (2.6-6.2) 15 2.7 (1.5-4.4) 12 2.1 (1.1-3.8) 21 3.8 (2.3-5.8) 
16-24  0 0 1 0.9 (0.0-4.9) 0 0 0 0 0 0 
25-44 7 3.9 (1.6-8.0) 3 1.7 (0.3-4.9) 2 1.1 (0.1-4.0) 2 1.1 (0.1-4.0) 4 2.2 (0.7-5.7) 
45-64 7 4.3 (1.7-8.9) 7 4.3 (1.7-8.9) 4 2.5 (0.7-6.3) 4 2.5 (0.7-6.3) 7 4.3 (1.7-8.9) 
65-74 2 3.6 (0.4-12.9) 4 7.1 (1.9-18.3) 4 7.1 (1.9-18.3) 1 1.8 (0.0-9.9) 5 8.9 (2.9-20.8) 
75-84 6 16.8 (6.2-36.5) 6 16.8 (6.2-36.5) 4 11.2 (3.0-28.6) 3 8.4 (1.7-24.5) 3 8.4 (1.7-24.5) 
  
 
CI, confidence interval; CAP, community-acquired pneumonia;  PCV7 CAP, CAP due to serotypes included in the 7-valent pneumococcal conjugate vaccine; additional PCV13 
CAP, CAP due to serotypes included in the 13-valent pneumococcal conjugate vaccine; other CAP, CAP due to ‘other’ serotypes 
Table 2: Incidence rates of CAP, pneumococcal CAP, and CAP due to PCV7, additional PCV13 and ‘other’ serotypes by study year 
 
















trend   IRR(95%CI) IRR(95%CI) IRR(95%CI) IRR(95%CI) IRR(95%CI)   
           
CAP 1.00 0.9(0.8-1.0) 0.7 (0.6-0.8) 1.1 (1.0-1.2) 0.7 (0.6-0.8) 0.96, 95%CI 0.94-0.99 0.016 
           
Pneumococcal CAP 1.00 0.8(0.6-0.9) 0.5 (0.4-0.6) 0.5 (0.4-0.6) 0.6 (0.5-0.7)  0.84, 95%CI 0.80-0.89 <0.001 
           
PCV7-serotype CAP 1.00 0.15 (0.07-0.29) 0.13 (0.06-0.27) 0.03 (0.01-0.13) 0.21 (0.12-0.38) 0.52, 95%CI 0.43-0.62 <0.001 
           
CAP due to additional PCV13 serotypes 1.00 1.08 (0.76-1.54) 0.76 (0.52-1.12) 0.75 (0.50-1.50) 0.59 (0.39-0.90) 0.87, 95%CI 0.80-0.95 0.002 
           
CAP due to 'other' serotypes 1.00 0.95 (0.54-1.70) 0.62 (0.33-1.19) 0.50 (0.25-1.00) 0.88 (0.49-1.57) 0.91, 95%CI 0.79-1.05 0.218 
           
‘Untyped’ pneumococcal CAP 1.00 1.04 (0.70-1.54) 0.65 (0.42-1.01) 0.67 (0.43-1.04) 0.90 (0.60-1.34) 0.94 (0.85-1.03) 0.171 
 
 
IRR, incidence rate ratio; CI, confidence interval; CAP, community-acquired pneumonia; PCV7, 7-valent pneumococcal conjugate vaccine; PCV13, 13-valent pneumococcal 
conjugate vaccine 
 





   Overall incidence per 100,000 population IRR 95%CI p value 
  Pre-PCV13 (2008-09) Post-PCV13 (2010-13)       
        
CAP 90.7 (83.0-99.0) 76.7 (72.6-81.0) 0.85 0.76-0.94 0.001 
        
Pneumococcal CAP 35.1 (30.4-40.4) 18.3 (16.3-20.5) 0.52 0.44-0.62 <0.001 
        
CAP due to PCV7 serotypes 11.1 (8.5-14.2) 1.4 (0.9-2.1) 0.12 0.08-0.20 <0.001 
        
CAP due to additional PCV13 serotypes 10.6 (8.0-13.6) 7.4 (6.2-8.8) 0.70 0.51-0.96 0.024 
        
CAP due to other serotypes 4.3 (2.8-6.4) 2.9 (2.1-3.8) 0.67 0.41-1.09 0.105 
 
CAP, community-acquired pneumonia; PCV7, 7-valent pneumococcal conjugate vaccine; PCV13, 13-valent pneumococcal conjugate vaccine 
 
Table 4: Comparison of incidence rates pre-PCV13 (2008-09) and post-PCV13 (2010-13) introduction 
 
 
   2008-09 2009-10 2010-11 2011-12 2012-13 
p value for linear trend 
in disease severity* 
         
CAP cohort (n=2229)      0.073 
         
Low severity 210 (41.5) 195 (44.4) 188 (52.4) 260 (46.4) 189 (51.8)   
Moderate severity 170 (33.6) 156 (35.5) 93 (25.9) 161 (28.7) 93 (25.5)   
High severity 126 (24.9) 88 (20.0) 78 (21.7) 139 (24.8) 83 (22.7)   
         
         
Pneumococcal cohort 
(n=653)      0.838 
         
Low severity 81 (41.3) 58 (38.7) 48 (48.0) 34 (37.0) 51 (44.3)   
Moderate severity 56 (28.6) 57 (38.0) 25 (25.0) 29 (31.5) 32 (27.8)   
High severity 59 (30.1) 35 (23.3) 27 (27.0) 29 (31.5) 32 (27.8)   
 
* using chi-squared analysis 
All values given as n(%) unless stated otherwise 
Low severity defined as CURB65 (confusion, urea>7 mmol/l, respiratory rate >30 breaths per minute, systolic blood pressure <90 mmHg or diastolic blood pressure ≤60 mmHg, 
age ≥65 years) 0-1; moderate severity CURB65=2; and high severity CURB65 ≥3 
 
Supplementary table 1: Disease severity by study year 
 
Serotype 2008-09 2009-10 2010-11 2011-12 2012-13 
        
8 19 16 13 8 14 
9N 0 1 0 0 1 
10A 0 0 0 0 1 
12F 2 0 1 0 1 
15A 0 0 0 2 0 
16F 0 0 0 0 1 
22F 0 3 0 1 1 
23B 0 0 1 0 0 
28F 1 0 0 0 0 
33F 1 2 0 0 1 
35B 1 0 0 1 0 
35F 0 1 0 0 0 
38 0 0 0 0 1 
        
Total 24 23 15 12 21 
 
Values represent number of adults 
Supplementary table 2: Non-PCV13 serotypes detected in hospitalised adults with pneumococcal CAP by study year 
 
  
  2008-09 2009-10 2010-11 2011-12 2012-13 
       
Escherichia coli 6 2 3 1 1 
Haemophilus influenzae 13 9 17 15 11 
Legionella pneumophilia 10 5 4 6 9 
Pseudomonas aeuruginosa 11 12 2 12 7 
Staphylococcus aureus 4 1 3 2 2 
Streptococcus pneumoniae (sputum only) 8 6 15 6 4 
Streptococcus pneumoniae 196 150 100 92 115 
Other organisms* 5 5 3 10 7 
Not defined 253 249 212 416 209 
       
Total 506 439 359 560 365 
 
*Other organisms include those isolated in <10 individuals each during the five-year period (including Klebsiella pneumoniae, Serratia Marcescens, enterobacter species and 
viruses) 
Supplementary table 3: Microbial aetiology of CAP by study year 
 
  
Year 1 (2008-09) Year 2 (2009-10) Year 3 (2010-11) Year 4 (2011-12) Year 5 (2012-13) 
n Incidence(95%CI) n Incidence (95%CI) n Incidence (95%CI) n Incidence (95%CI) n Incidence (95%CI) 
CAP 506 90.7 (83.0-99.0) 439 78.7 (71.5-86.4) 359 64.4 (57.9-71.4) 560 100.4 (92.3-109.1) 365 65.4 (58.9-72.5) 
16-24  16 14.0 (8.0-22.7) 6 5.3 (1.9-11.4) 11 9.6 (4.8-17.2) 23 20.1 (12.8-30.2) 15 13.1 (7.4-21.6) 
25-44 50 27.9 (20.7-36.7) 60 33.4 (25.5-43.0) 51 28.4 (21.2-37.4) 61 34.0 (26.0-43.7) 49 27.3 (20.2-36.1) 
45-64 97 59.7 (48.4-72.8) 91 56.0 (45.1-68.7) 82 50.4 (40.1-62.6) 131 80.6 (67.4-95.6) 95 58.4 (47.3-71.4) 
65-74 113 201.4 (166.0-242.2) 89 158.7 (127.4-195.2) 77 137.2 (108.3-171.6) 107 190.7 (156.3-230.5) 77 137.2 (108.3-171.6) 
75-84 129 360.3 (300.8-428.1) 111 310.1 (255.1-373.4) 91 254.2 (204.7-312.1) 148 413.4 (349.5-485.6) 88 245.8 (197.2-302.8) 
85+ 101 1052.1 (856.9-1278.4) 82 854.2 (679.3-1060.2) 47 489.6 (359.7-651.0) 90 937.5 (753.9-1152.3) 41 427.1 (306.5-579.4) 
Spn CAP 
               
196 35.1 (30.4-40.4) 150 26.9 (22.8-31.6) 100 17.9 (14.6-21.8) 92 16.5 (13.3-20.2) 115 20.6 (17.0-24.8) 
16-24  6 5.2 (1.9-11.4) 4 3.5 (1.0-9.0) 3 2.6 (0.5-7.7) 3 2.6 (0.5-7.7) 6 5.2 (1.9-11.4) 
25-44 22 12.3 (7.7-18.6) 26 14.5 (9.5-21.2) 22 12.3 (7.7-18.6) 10 5.6 (2.7-10.2) 19 10.6 (6.4-16.5) 
45-64 40 24.6 (17.6-33.5) 31 19.1 (13.0-27.1) 24 14.8 (9.5-22.0) 20 12.3 (7.5-19.0) 26 16.0 (10.4-23.4) 
65-74 39 69.5 (49.4-95.0) 28 49.9 (33.2-72.1) 22 39.2 (24.6-59.4) 20 35.6 (21.8-55.1) 23 41.0 (26.0-61.5) 
75-84 49 136.9 (101.3-181.0) 34 95.0 (65.8-132.7) 18 50.3 (29.8-79.5) 24 67.0 (43.0-99.8) 25 69.8 (45.2-103.1) 
85+ 40 416.7 (297.7-567.4) 27 281.2 (185.3-409.2) 11 114.6 (57.2-205.0) 15 156.2 (87.4-257.7) 16 166.7 (95.3-270.7) 
PCV7 CAP 
               
62 11.1 (8.5-14.2) 9 1.6 (0.7-3.1) 8 1.4 (0.6-2.8) 2 0.4 (0.0-1.3) 13 2.3 (1.2-4.0) 
16-24  0 0 1 0.9 (0.0-4.9) 0 0 0 0 0 0 
25-44 4 2.2 (0.6-5.7) 0 0 1 0.6 (0.0-3.1) 0 0 3 1.7 (0.3-4.9) 
45-64 12 7.4 (3.8-12.9) 3 1.8 (0.4-5.4) 2 1.2 (0.0-4.4) 1 0.6 (0.0-3.4) 1 0.6 (0.0-3.4) 
65-74 15 26.7 (15.0-44.1) 1 1.8 (0.0-9.9) 3 5.3 (1.1-15.6) 1 1.8 (0.0-9.9) 4 7.1 (1.9-18.3) 
75-84 14 39.1 (21.4-65.6) 1 2.8 (0.1-15.6) 1 2.8 (0.1-15.6) 0 0 2 5.6 (0.7-20.2) 




               
59 10.6 (8.0-13.6) 64 11.5 (8.8-14.6) 45 8.1 (5.9-10.8) 44 7.9 (5.7-10.6) 35 6.3 (4.4-8.7) 
16-24  1 0.9 (0.0-4.9) 1 8.7 (4.2-16.1) 2 1.7 (0.2-6.3) 3 2.6 (0.5-7.7) 3 2.6 (0.5-7.7) 
25-44 9 5.0 (2.3-9.5) 15 8.4 (4.7-13.8) 13 7.2 (3.9-12.4) 4 2.2 (0.6-5.7) 6 3.3 (1.2-7.3) 
45-64 10 6.2 (3.0-11.3) 16 9.8 (5.6-16.0) 11 6.7 (3.4-12.1) 12 7.4 (3.8-12.9) 9 5.5 (2.5-10.5) 
65-74 13 23.2 (12.3-39.6) 11 19.6 (9.8-35.1) 10 17.8 (8.6-32.8) 13 23.2 (12.3-39.6) 7 12.5 (5.0-25.7) 
75-84 16 44.7 (25.6-72.6) 11 30.7 (15.3-55.0) 4 11.2 (3.0-28.6) 7 19.6 (7.9-40.3) 8 22.3 (9.6-44.0) 
85+ 10 104.2 (50.0-191.6) 10 104.2 (50.0-191.6) 5 52.1 (16.9-121.6) 5 52.1 (16.9-121.6) 2 20.8 (2.5-75.3) 
Other CAP 
               
24 4.3 (2.8-6.4) 23 4.1 (2.6-6.2) 15 2.7 (1.5-4.4) 12 2.1 (1.1-3.8) 21 3.8 (2.3-5.8) 
16-24  0 0 1 0.9 (0.0-4.9) 0 0 0 0 0 0 
25-44 7 3.9 (1.6-8.0) 3 1.7 (0.3-4.9) 2 1.1 (0.1-4.0) 2 1.1 (0.1-4.0) 4 2.2 (0.7-5.7) 
45-64 7 4.3 (1.7-8.9) 7 4.3 (1.7-8.9) 4 2.5 (0.7-6.3) 4 2.5 (0.7-6.3) 7 4.3 (1.7-8.9) 
65-74 2 3.6 (0.4-12.9) 4 7.1 (1.9-18.3) 4 7.1 (1.9-18.3) 1 1.8 (0.0-9.9) 5 8.9 (2.9-20.8) 
75-84 6 16.8 (6.2-36.5) 6 16.8 (6.2-36.5) 4 11.2 (3.0-28.6) 3 8.4 (1.7-24.5) 3 8.4 (1.7-24.5) 
85+ 2 20.8 (2.5-75.3) 2 20.8 (2.5-75.3) 1 10.4 (0.2-58.0) 2 20.8 (2.5-75.3) 2 20.8 (2.5-75.3) 
Untyped 
Spn CAP 
               
49 8.8 (6.5-11.6) 51 9.1 (6.8-12.0) 32 5.7 (3.9-8.1) 33 5.9 (4.1-8.3) 44 7.9 (5.7-10.6) 
16-24  5 4.4 (1.4-10.2) 1 0.9 (0.0-4.9) 1 0.9 (0.0-4.9) 0 0 3 2.6 (0.5-7.7) 
25-44 2 1.1 (0.1-4.0) 7 3.9 (1.6-8.0) 6 3.3 (1.2-7.3) 3 1.7 (0.3-4.9) 6 3.3 (1.2-7.3) 
45-64 10 6.1 (3.0-11.3) 5 3.1 (1.0-7.2) 7 4.3 (1.7-8.9) 3 1.8 (0.4-5.4) 9 5.5 (2.5-10.5) 
65-74 9 16.0 (7.3-30.4) 12 21.4 (11.0-37.4) 5 8.9 (2.9-20.8) 5 8.9 (2.9-20.8) 7 12.5 (5.0-25.7) 
75-84 12 33.5 (17.3-58.6) 16 44.7 (25.6-72.6) 9 25.1 (11.5-47.7) 14 39.1 (21.4-65.6) 10 27.9 (13.4-51.4) 
85+ 11 114.6 (57.2-205.2) 10 104.2 (50.0-191.6) 4 41.7 (11.3-106.7) 8 83.3 (36.0-164.2) 9 93.8 (42.9-178.0) 
 
* pneumonia due to dual serotypes were detected in 2, 3 , 0, 1 and 2 adults during years 1, 2, 3, 4 and 5 respectively 
 
Supplementary table 4:  Incidence rates of CAP, pneumococcal CAP, and CAP due to PCV7, additional PCV13, ‘other’ serotypes and ‘untyped’ serotypes by study 
year 
 
  2008-09 2009-10 2010-11 2011-12 2012-13 
Serotype 8 19 16 13 8 14 
Non-PCV13 serotypes in bacteraemic adults 5 7 2 4 7 
Extrapolated data from 'untyped' pneumococcal cohort* 14 15 9 9 13 
Total 38 38 24 21 34 
 
*Data extrapolated based on the assumption that 28.7% of adults with ‘untyped’ pneumococcal CAP had non-PCV13 serotypes 
 







CAP, community-acquired pneumonia; PCV7, 7-valent pneumococcal conjugate vaccine; PCV13, 13-valent pneumococcal conjugate vaccine 
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